Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542

Japan

Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

Evaluate European Drug Forecasts to 2022

Real-world, country level historic product sales and consensus based forecasts.

Conduct European market sizing, R&D horizon scanning and price comparison utilising real world government and company reported sales data with country level, consensus based product forecasts to 2022.



Evaluate European Drug Forecasts to 2022 

EvaluatePharma European Drug Forecasts offer a single solution for business development and licensing, commercial and corporate strategy, consultants and investment banks:


European Market Sizing
Forecasts for 300+ marketed products – market value €111bn in 2022

  • Conduct future market assessment
  • Map future trends of key marketed drugs

Market Assessment
Historical government and company reported sales data - EU 5 and other key markets

  • Map key pipeline assets that are likely to launch by 2022 and measure impact
  • Identify new medicines and how they impact therapy areas

R&D Horizon Scanning
Forecasts for 500+ R&D products – market value €160 bn in 2022

  • Compare product performance across key European markets
  • Map update trends and drivers across European countries

Pricing Comparison Analysis Across Countries
Government reported pricing and volume analysis (EU 5 and other key markets)

  • Perform comparative analysis of prices across EU countries
  • Use price/DDD benchmark to inform quick assessment of new assets

European Drug Forecasts are available as an add on module to EvaluatePharma.


For more information:

    Download Report: Pharmaceutical Innovation in Europe      Download Infographic: European Pharma Market Outlook to 2022     Download Brochure: European Drug Forecasts                   

Contact us today for a demo